Biological Information
Background Information:
SCF Skp2/Cks1 complex is a multi-subunit E3 ubiquitin ligase belonging to the Skp1–Cullin–F-box (SCF) family. It consists of Skp1, Cul1, Rbx1, and the F-box protein Skp2, which functions as the substrate-recognition subunit. Cks1 acts as an adaptor that enhances substrate binding, particularly to phosphorylated targets such as the cyclin-dependent kinase inhibitor p27. The SCF Skp2/Cks1 complex mediates ubiquitin-dependent degradation of key cell-cycle regulators, including p27, p21, and p57, thereby promoting G?/S phase transition and cellular proliferation. Dysregulated Skp2 or Cks1 expression is frequently observed in cancers, correlating with poor prognosis, enhanced proliferation, and resistance to apoptosis.
Target Class:
Ubiquitination-related
Family:
F-box protein
Sub Family:
E3 Ligase
Protein Name:
Skp2
Protein Aliases:
FBXL1; p45skp2 (Skp2)
Accession Number:
NM_005983.2 (Skp2); NM_170679.2 (Skp1); NM_003592.2 (Cul1); NM_014248.2 (Rbx1); NM_001826.2 (Cks1)
UniProt Number:
Q13309 (Skp2)
Gene Name:
SKP2 (Skp2)
Gene ID:
6502 (Skp2)
Gene Aliases:
p45; FBL1; FLB1; FBXL1 (Skp2)
Target Species:
Human
Usage
Product Type:
Enzymes
Application:
Drug Discovery & Development
Storage Conditions:
1 year at -70°C
Usage disclaimer:
These products may be covered by issued US and/or foreign patents, patent applications and subject to a Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.
Assay Information
Assay Type:
Enzymatic
Assay Measures:
ECL
Bioassay Data
Trademark Statement:
For Research Use Only
Clinical Relevance
Therapeutic Area:
Oncology